President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
The meeting comes amid months of stalled trade talks between Washington and New Delhi, resulting in both sides taking retaliatory measures.Asia Politicsread more
Gas prices could rise by about 20 cents per gallon "starting tomorrow," oil analyst Andy Lipow says Monday.Oil and Gasread more
Some operators are cashing in on the CBD craze by substituting cheap and illegal synthetic marijuana for natural CBD in vapes and edibles such as gummy bears, an AP...Health and Scienceread more
(Adds details from court hearing)
BOSTON, June 7 (Reuters) - A unit of Insys Therapeutics Inc pleaded guilty on Friday to fraud charges as part of an $225 million deal with the U.S. Justice Department resolving claims that the drugmaker bribed doctors to prescribe an addictive opioid medication.
The plea, in federal court in Boston by the Chandler, Arizona-based Insys' operating subsidiary, came in one of the few criminal prosecutions to date of a corporation accused of helping fuel the nation's deadly opioid epidemic.
The plea deal was announced on Wednesday, a month after a federal jury found wealthy Insys founder John Kapoor and four other former executives and managers guilty of engaging in a vast racketeering conspiracy.
Insys is facing growing financial pressures as a result of the U.S. probe and a decline in sales of its flagship fentanyl pain product, Subsys, which it has said could prompt the company to seek bankruptcy protection.
Beyond the plea by subsidiary Insys Pharma Inc, Insys has also entered into a five-year deferred prosecution agreement with the government and agreed to pay $30 million in the criminal case and $195 million to resolve civil claims.
U.S. District Judge Rya Zobel approved the parent company's deferred prosecution agreement at Friday's hearing and scheduled sentencing for the subsidiary for July 10.
Insys in a statement said it believes the deal is in its best interests. Kapoor and his co-defendants deny wrongdoing and are expected to appeal.
Subsys is an under-the-tongue spray the U.S. Food and Drug Administration approved in 2012 only for treating pain in cancer patients. Its main ingredient, fentanyl, is an opioid 100 times stronger than morphine.
Prosecutors alleged that while Kapoor served as Insys' chairman, the company from 2012 to 2015 paid doctors and other medical practitioners bribes in exchange for prescribing Subsys to their patients, often to those who did not have cancer.
Insys did so by paying medical practitioners to act as speakers at sham events ostensibly meant to educate clinicians about Subsys but that were often just social gatherings at high-priced restaurants with no real attendees.
Those practitioners include a former New Hampshire physician assistant, Christopher Clough, who prosecutors say received $44,000. Payments to Clough form the basis of the plea by the subsidiary to five counts of mail fraud.
Clough was sentenced on Monday to four years in prison after being convicted of accepting kickbacks from Insys. He plans to appeal. (Reporting by Nate Raymond in Boston Editing by Bill Berkrot and Steve Orlofsky)